Screening And Baseline Characteristics Of A Ph2b/3 Randomized, Placebo-Controlled Trial Of Emestedastat In Mild/Moderate AD

Xanamem (emestedastat) - Actinogen Medical

Jack Taylor1; Paul Rolan2,1; Mark Jaros3; XanaMIA trial Investigators, Christopher Chen4; Dana Hilt1

Jun 30, 2026